Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis

Clinical and Molecular Allergy

Itsuro Kazama¹ 

[1] School of Nursing, Miyagi University, 1-1 Gakuen, Taiwa-cho, Kurokawa-gun, 981-3298, Miyagi, Japan;

关键词: Coronavirus disease 2019 (COVID-19);    Vaccines;    Anaphylaxis;    Mast cell stabilizer;   

DOI  :  10.1186/s12948-021-00162-9

来源: Springer

【 摘 要 】

To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach. However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis. In anaphylaxis, the exposure to the allergen causes a sudden release of chemical mediators from mast cells, for which adrenaline is the drug of first choice. In our previous basic studies, in addition to adrenaline, anti-allergic drugs (olopatadine, loratadine, tranilast and ketotifen), antibiotics (clarithromycin), corticosteroids (hydrocortisone and dexamethasone) and certain food constituents (caffeine and catechin) inhibited the process of exocytosis and showed their effectiveness as highly potent mast cell stabilizers. In these studies, since mast cells were pre-incubated with these drugs or the food constituents before exocytosis was induced, the findings strongly indicated their prophylactic efficacy in stabilizing mast cells. Considering such pharmacological properties of these commonly prescribed medications or the food constituents, their prophylactic use may potentially be beneficial in preventing anaphylaxis caused by COVID-19 vaccination.

【 授权许可】

CC BY